Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

4.55USD
1:30am IST
Change (% chg)

$0.09 (+2.02%)
Prev Close
$4.46
Open
$4.49
Day's High
$4.58
Day's Low
$4.31
Volume
344,779
Avg. Vol
438,227
52-wk High
$13.71
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Dynavax Technologies Q2 Loss Per Share $0.66
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Dynavax Technologies Corp ::DYNAVAX ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.66.Q2 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.UPDATED NET PRODUCT REVENUE GUIDANCE OF $32-$36 MILLION FOR FULL YEAR 2019.COMPANY IS EXPLORING STRATEGIC ALTERNATIVES FOR ITS IMMUNO-ONCOLOGY PORTFOLIO.IN QUARTER RECOGNIZED RESTRUCTURING CHARGES OF $8.8 MILLION AND REMAINING $0.6 MILLION IS EXPECTED TO BE RECOGNIZED BY END OF 2019.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $140.5 MILLION AT JUNE 30, 2019..  Full Article

Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Dynavax Technologies Corp ::DYNAVAX PRESENTS PHASE 1B DATA ON INHALED DV281 TLR9 AGONIST AT THE 2019 AACR ANNUAL MEETING.DYNAVAX TECHNOLOGIES CORP - TARGET ENGAGEMENT WAS OBSERVED AT ALL DOSE LEVELS.DYNAVAX TECHNOLOGIES - INHALED DV281 IN COMBINATION WITH SYSTEMIC NIVOLUMAB WAS WELL TOLERATED IN A POPULATION OF HEAVILY PRE-TREATED NSCLC PATIENTS.DYNAVAX TECHNOLOGIES CORP - NO IMMUNE-RELATED ADVERSE EVENTS SUCH AS PNEUMONITIS HAVE BEEN REPORTED..  Full Article

Dynavax - Due To Sciabacucchi Decision, Do Not Currently Intend To Enforce Foregoing Federal Forum Selection Provision Unless Decision Reversed
Saturday, 2 Mar 2019 

March 1 (Reuters) - Dynavax Technologies Corp ::DYNAVAX - DUE TO SCIABACUCCHI DECISION, DO NOT CURRENTLY INTEND TO ENFORCE FOREGOING FEDERAL FORUM SELECTION PROVISION UNLESS DECISION REVERSED.  Full Article

Dynavax Technologies-AstraZeneca Informed Co Initial High-Level Results From Phase 2A Study Indicate Azd1419 Treatment Did Not Meet Primary Endpoint
Friday, 30 Nov 2018 

Nov 29 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES - ASTRAZENECA INFORMED CO INITIAL HIGH-LEVEL RESULTS FROM PHASE 2A STUDY INDICATE AZD1419 TREATMENT DID NOT MEET PRIMARY ENDPOINT.DYNAVAX TECHNOLOGIES CORP - ASTRAZENECA WILL NOW REVIEW FULL DATA BEFORE DECIDING ON NEXT STEPS FOR AZD1419 PROGRAM.DYNAVAX TECHNOLOGIES SAYS AZD1419 TREATMENT APPEARED TO BE SAFE & WELL TOLERATED & STUDY CONFIRMED ACTIVATION OF TLR9 PATHWAY - SEC FILING.  Full Article

Dynavax Technologies Q2 Loss Per Share $0.63
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.63.Q2 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.Q2 SALES $1.3 MILLION VERSUS I/B/E/S VIEW $1.6 MILLION.  Full Article

Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Dynavax Technologies Corp :Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults.Dynavax Technologies Corp - ‍expects to commercially launch Heplisav-B in United States in Q1 of 2018​.  Full Article

Dynavax reports Q3 loss per share $0.38
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Dynavax Technologies Corp :Dynavax reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - Qtrly total revenue $53,000 versus $162,000‍​.Dynavax Technologies - ‍Cash, cash equivalents & marketable securities were $191.7 million at Sept 30, 2017 compared to $81.4 million at Dec 31, 2016​.  Full Article

Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Dynavax Technologies Corp :Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy.Dynavax Technologies - ‍dose escalation study is expected to enroll about 24 patients in 5 cohorts with advanced NSCLC.  Full Article